TABLE 1.

All-cause mortality through day 42 classified by baseline drug MICs for Aspergillus sp. isolates alone or with other fungal pathogens: CLSI and EUCAST methodologiesa^a

Methodology, treatment, and target	No. of isolates with indicated MIC (μg/ml)/total no. of isolates (% of total)b
	0.25	0.5	1	2	4	8	16	>16
CLSI
Isavuconazole
Aspergillus spp. only	1/9 (11)	0/9	3/15 (20)	1/7 (14)	0/6	0/2		1/1 (100)
Multiple fungal spp.c	0/1			0/1		0/3	1/1 (100)
Voriconazole
Aspergillus spp. only	1/1 (100)	3/5 (60)	0/11	3/5 (60)
Multiple fungal spp.d						0/1
EUCAST
Isavuconazole
Aspergillus spp. only	1/8 (13)	0/7	2/16 (17)	2/12 (17)	0/3	0/2		1/1 (100)
Multiple fungal spp.c	0/1		0/1	0/1	0/1		1/1 (100)	0/1
Voriconazole
Aspergillus spp. only		4/10 (40)	1/8 (13)	1/3 (33)			1/1 (100)
Multiple fungal spp.d					0/1

^aSee the supplemental materials for ACM data for individual and multiple Aspergillus spp. Only baseline samples are included in this summary. CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; MIC, minimum inhibitory concentration.

^bThe denominator represents the number of patients whose isolates had that drug MIC (where patients had multiple isolates, the isolate with the highest baseline drug MIC was used); the numerator denotes the number of patients who died. The outcome for a patient whose last known survival status was determined before day 42 or was missing and whose last assessment day was before day 42 was treated as representing death.

^cData include Lichtheimia corymbifera (n = 2 patients), Fonsecaea monophora, Chaetomium brasiliense, and Rhizopus oryzae.

^dData include Penicillium piceum.